Worldpharma Biotech will manufacture the first medical cannabis products for clinical trials in Spain with Tilray GMP certified medical cannabis
Tilray Medical Cannabis will now be available in 17 countries around the world
NANAIMO, British Columbia – (BUSINESS WIRE) – Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, announced today that it has an agreement with Worldpharma Biotech (” Worldpharma “). through its wholly owned subsidiary Tilray Portugal Unipessoal Lda. (“Tilray Portugal”) to export GMP (Good Manufacturing Processes) certified medical cannabis from Portugal to Spain. The shipment marks the first import of medical cannabis to Spain by Worldpharma and the 17th country to receive Tilray medical cannabis in the world.
The Spanish Food and Drug Administration Agencia Española de Medicamentos y Productos Sanitorios (AEMPS) has approved Worldpharma to import Tilray’s GMP-certified medicinal cannabis as raw material from its plant in Portugal to Spain. Using Tilray’s pharmaceutical grade cannabis, Worldpharma will develop medicinal cannabis products for clinical trials in Spanish hospitals for diseases such as Alzheimer’s, Parkinson’s and skin infections.
Brendan Kennedy, Tilray’s Chief Executive Officer, said: “We are incredibly honored to be the first licensed cannabis company to supply medical cannabis to Spain. As we continue to work with regulators around the world, we are grateful to be working with the AEMPS and established pharmaceutical companies like Worldpharma Biotech in the distribution of Tilray medical cannabis. ”
Juan Jose Garcia Miquel, Founder of World Pharma Biotech, said: “We are very excited to have signed a contract with Tilray for the supply of cannabis biomass to supply our extraction and purification laboratory with GMP certified quality products that meet the highest EU standards – and Spanish pharmacology standards. We intend to work with companies with the highest pharmaceutical quality standards to give full confidence to doctors and patients. It has been impossible to match this level of quality from other cannabis approved companies in Spain. ”
Sascha Mielcarek, Tilray’s General Manager for Europe, said: “We are very excited to be working with Worldpharma. Tilray is re-establishing itself as a key player with solid expertise in patient wellbeing. Tilray applies the highest medical standards throughout its supply chain, providing sustainable and safe access to pharmaceutical-grade medical cannabis for patients in need and paving the way for future medical cannabis care standards. ”
Tilray has a groundbreaking track record as a company committed to making GMP-certified pharmaceutical grade medical cannabis products available to patients in need worldwide. Tilray was the first to export medical cannabis from North America and imported medical cannabis product to the EU in 2016.
Tilray’s EU campus in Portugal is a multi-faceted manufacturing facility that includes research and quality control laboratories, packaging and distribution locations for medical cannabis. It also serves as a hub for Tilray’s clinical research and product development efforts across Europe. Tilray has entered into sales and distribution agreements for the supply of medical cannabis via important distribution channels for pharmaceuticals throughout Germany and the EU, which should give patients access to Tilray’s GMP-certified medical cannabis.
Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids and currently serves tens of thousands of patients and consumers in 17 countries on five continents.
About WorldPharma Biotech
World Pharma Biotech was founded in Valencia, Spain in 2014 and focuses on plant-based ingredients for the nutraceuticals, cosmetics and pharmaceuticals industries. The company is located in the University of Valencia Science Park, a center of spin-offs and start-ups from the University of Valencia. The main focus of the extraction and purification laboratory is on the production of active pharmaceutical ingredients from cannabis for the European pharmaceutical and dermo-cosmetics industry.
This press release contains “forward-looking statements” within the meaning of the US Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws or collectively forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”. “intend”, “plan”, “forecast”, “project”, “estimate”, “forecast” and other similar expressions. Forward-looking statements are not a guarantee of future performance and are based on a number of estimates and assumptions made by management, taking into account management’s experience and perception of trends, current conditions and expected developments, and other factors that management may consider in the circumstances considers relevant and appropriate, including assumptions regarding current and future European market conditions, the current and future regulatory environment, and future permits and approvals. Actual results, performance or accomplishments could differ materially from the forward-looking statements contained or implied in this press release. Accordingly, you should not place undue reliance on any such forward-looking statements, and they are not guarantees of future results. Under the heading “Risk Factors” in Tilray’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2020, please see material risk factors, which could cause actual results to differ materially from the forward-looking information. Tilray undertakes no obligation to update any forward-looking statements contained herein except in accordance with applicable securities laws.
For more information:
How to request an interview opportunity: